The story of Viagra and its originator, copyright, presents a fascinating picture for prospective investors. While the iconic drug initially fueled enormous revenues , its exclusivity has ended, leading to competing alternatives flooding the market . This erosion in pricing presents a significant challenge for copyright and any fund considering a h